UPCOMING SYMPOSIUM: 3rd Global Genomic Medicine Collaborative Conference
3rd Global Genomic Medicine Collaborative Conference
Implementing Genomic Medicine into Practice
April 27-29, 2017, Athens, Greece
The 3rd Global Genomic Medicine Collaborative Conference will be organized in Athens, Greece, April 27-29, 2017.
The meeting will be organized by the Global Genomic Medicine Collaborative and the Golden Helix Foundation, as the local host. The 3rd Global Genomic Medicine Collaborative Conference is the first to be organized in Europe, following the successful events in the United States in 2014 and Singapore in 2015 and will focus on the implementation of Genomic Medicine into clinical practice.
Leaders in Genomic Medicine across the globe will be attending this highly interactive meeting to define collaborative projects and strategies that will serve the global community to use genomic advances to improve clinical care. Representatives from the developed and the developing world will share challenges and strategies to overcome them. In addition we will be convening industry and leaders of large genomic consortia to engage in the dialog about the potential to impact health care delivery.
The 3rd Global Genomic Medicine Collaborative Conference organizing Committee
The Global Genomic Medicine Collaborative
The Global Genomic Medicine Collaborative (G2MC) is an action collaborative among global leaders in the implementation of genomic medicine in clinical care. Arising from the 2014 Global Leaders in Genomic Medicine Summit, the purpose of G2MC is to identify opportunities and foster global collaborations for enabling the demonstration of value and the effective use of genomics in medicine. Engaging multiple stakeholders across the globe, the G2MC group, under the auspices of the Roundtable on Genomics and Precision Health, seeks to improve global health by catalyzing the implementation of genomic tools and knowledge into health care delivery globally. To accomplish these goals, seven working groups were created, including communications, education, evidence, IT/bioinformatics, pharmacogenomics, policy, and a steering group to guide and support efforts among working groups.
Specifically, it is intended to:
- Serve as nexus, clearinghouse, and knowledge base for genomic medicine activities globally;
- Develop opportunities for global genomic medicine demonstration projects (implementation and outcomes research) and;
- Capture and disseminate best practices for genomic medicine (in bioinformatics, education, evidence, pharmacogenomics, policy) across the global genomic medicine community.
The purpose and goals of the Global Genomic Medicine Collaborative (G2MC):
- Develop projects with global participation
- Opportunities to disseminate learnings for genomic medicine implementation
- Educational platforms to support genomic medicine projects
- Community engagement and access to global genomic medicine expertise
- Creation of a registry or catalog of genomic medicine projects and programs across the globe to stimulate collaboration and efficiency in translation
- Be a global policy forum for genomic medicine
- Mapping the global genomic medicine landscape particularly as it relates to policy and implementation
- Global eradication of preventable Stevens Johnson Syndrome/Toxic Epidermal Necrolysis
2nd G2MC Conference; November 6-7, 2015, Singapore - Implementing Genomic Medicine into Practice
The meeting objectives were to:
- Highlight nations or organizations around the world that are implementing genomic medicine into practice
- Foster/facilitate collaborations to enable the implementation of genomic medicine
- Highlight best practices and lessons learned to enable others to effectively implement genomic medicine approaches
- Identify and develop solutions for overcoming obstacles to genomic medicine implementation
- Identify and discuss regulations and policies that impact the implementation of genomic medicine
- Create a global tool box for implementation of genomic medicine into practice
1st G2MC Conference; January 8-9, 2014, Washington DC, USA - Global Leaders in Genomic Medicine
The goals of the meeting were to:
- Identify areas of active translational and implementation research, potential common strategies, and opportunities for collaborative efforts.
- Identify common barriers to implementation of genomics in healthcare and a policy agenda relevant to advances in the field.
- Identify nations with unique capabilities (such as national healthcare systems) that may allow rapid implementation and measures of key outcomes.
- Discuss opportunities (such as national healthcare system) that may allow rapid implementation and measures of key outcomes.
Venue of the 3rd Global Genomic Medicine Collaborative Conference
The 3rd Global Genomic Medicine Collaborative Conference will be held in the DIVANI Apollon Palace and Thalasso*****.
Divani Apollon Palace and Thalasso is a member of the Leading hotels of the world. This is a luxury beach resort in Athens situated in the exclusive area of Vouliagmeni, just 18km from the city centre. Guests enjoy, the pleasure of a private beach and an award winning Spa, the only one offering Thalassotherapy in the whole Attica region and one of the best Thalassotherapy centers in the Mediterranean.
Divani Apollon Palace and Spa is an excellent hotel for both leisure and business and offers quiet luxury at the prestigious Athenian Riviera.
Here is a short video about Athens
Geoff Ginsburg (Duke University School of Medicine, Durham, NC, USA; Co-Chair)
Robyn Ward (University of Queensland, Queensland, Australia; Co-Chair)
George P. Patrinos (University of Patras, Patras, Greece; Local Chair)
To be announced soon
Please note that the Scientific Program is currently being compiled and will be announced shortly.
Click here to register and submit an abstract.
Click here to register without submitting an abstract.
Click here to reserve your accommodation at the DIVANI Apollon Palace and Thalasso *.
* A special code to benefit from the discounted rate will be provided to the delegates of the 3rd G2MC Conference.